KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Bionano Genomics (BNGO) EBT (2017 - 2025)

Bionano Genomics (BNGO) has disclosed EBT for 9 consecutive years, with -$7.9 million as the latest value for Q4 2025.

  • Quarterly EBT rose 61.59% to -$7.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$26.3 million through Dec 2025, up 76.58% year-over-year, with the annual reading at -$26.3 million for FY2025, 76.58% up from the prior year.
  • EBT hit -$7.9 million in Q4 2025 for Bionano Genomics, up from -$8.5 million in the prior quarter.
  • In the past five years, EBT ranged from a high of -$3.1 million in Q1 2025 to a low of -$112.5 million in Q3 2023.
  • Historically, EBT has averaged -$29.0 million across 5 years, with a median of -$29.3 million in 2021.
  • Biggest five-year swings in EBT: tumbled 254.07% in 2023 and later skyrocketed 90.16% in 2025.
  • Year by year, EBT stood at -$28.7 million in 2021, then decreased by 28.4% to -$36.9 million in 2022, then dropped by 19.13% to -$43.9 million in 2023, then soared by 53.19% to -$20.6 million in 2024, then skyrocketed by 61.59% to -$7.9 million in 2025.
  • Business Quant data shows EBT for BNGO at -$7.9 million in Q4 2025, -$8.5 million in Q3 2025, and -$6.8 million in Q2 2025.